
Free Daily Podcast Summary
by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
A weekly discussion of all things biotech – breaking news, data, deals, and FDA actions – with a community of biotech industry leaders and experts. Join the live streams hosted by @BiotechCH, @daphnezohar, @bradloncar and @biotech1 on Twitter Spaces every Friday at 12pm ET.
The most recent episodes — sign up to get AI-powered summaries of each one.
On this week’s episode, Graig Suvannavejh, Tim Opler, BrianSkorney, Chris Garabedian, and Matt Gline opened with a look at the biotech market, with the XBI up roughly 17% to 18% year to date, though the group noted that AI-driven demand for capital and the possibility of an AI bubble are weighing on sentiment. The co-hosts then discussed expectations for 2027 as a significant M&A year, following conversations with pharma M&A leaders at the Jefferies Global Healthcare Conference. The group also covered the withdrawal of Heidi Overton’s FDA Commissioner nomination and what the uncertainty could mean for agency stability and volatility. Next, they discussed market rumors of a potential Sanofi acquisition of Insmed, including Brinsupri’s performance and raised guidance, and what a deal of that size could signal for the broader M&A landscape. The group also covered Lilly’s oncology deals with Stipple Bio and Calytrix, and the growing opacity of biobucks headlines and undisclosed upfront payments. Looking ahead, they considered how AI and drug development in China could push US biotech to reinvent itself. The episode closed with SELLAS’ positive Phase 3 data for its off-the-shelf cancer vaccine and the questions that remain around the data. *This episode aired on November 20, 2026.
On this week’s episode, Eric Schmidt, Yaron Werber, PaulMatteis, and Kate Haviland opened with a look at the biotech market, with the XBI up roughly 25% year to date, though it feels much worse to many buy-side clients. The group discussed the midterm elections, weighing a potential blue wave against a market pricing in two more rate hikes. They also previewed next week’s Senate vote on Dr. Heidi Overton’s nomination as FDA commissioner, with Paul sharing his conversation with former FDA Commissioner Scott Gottlieb at the Stifel Healthcare Conference, where Gottlieb expressed optimism about her confirmation and her grasp of the agency’s need to rehire and rebuild expertise. The co-hosts then discussed the longer-term future of MFN deals, including sunset provisions and the question of whether the policy returns. The conversation turned to drug launches, covering how companies set expectations through pre-launch conversations with clinicians, office staff, and patients, and whether expert network physicians are a representative sample. The group also covered forecast guidance as both an art and a science, annual market-size updates, Blueprint’s Ayvakit launch, and the friction of physician habit change, including the last mile and practice economics. The episode closed with an overview of PepGen’s DM1 data. *This episode aired on November 13, 2026.
On this week’s episode, Brian Skorney, Paul Matteis, Yaron Werber, and Adam Feuerstein opened with a look at what the midterm results could mean for biotech, covering the macro backdrop, the FDA, and drug pricing. The conversation then turned to Vertex’s povetacicept ahead of a potential IgAN approval at the end of November, and the competitive landscape as Vertex enters a market with two formidable competitors. In earnings news, the group discussed Revolution Medicines’ strong Q3 launch sales for Rasonque, which doubled market predictions, and the safety questions and possible label changes facing Neurocrine’s Vykat. The group also covered the race for the first FDA approval of a psilocybin depression treatment, with Compass nearing NDA completion and a reported filing from the Usona Institute, as well as Novartis’ update on tumor cases in Zolgensma-treated patients. The episode closed with the Phase 3 miss for Novartis and Ionis’ pelacarsen despite significant Lp(a) reduction, and what to watch for at AHA 2026 and ASH 2026. This episode aired on November 6, 2026.
On this week's episode, Chris Garabedian, Graig Suvannavejh, Sam Fazeli, Brian Skorney, and Yaron Werber opened with the M&A outlook from recent pharma earnings, with optimism for a stronger fourth quarter than the third. The group discussed Alnylam's post-earnings stock drop and the commercial challenges of launching its own drug. Next, Anthropic's acquisition of Mithril Medicine, a one-person company, and the unveiling of its founder, X user @Prof_Oak_, as Cody Tranbargar sparked a debate among the co-hosts on AI in biotech, with Amgen's fast trial enrollment cited as an early proof point. The group then covered a mixed IPO year, with early-stage companies still drawing investor appetite, and weighed the market outlook against interest rate and post-midterm tariff risks. They also discussed Plowshare Therapies' philanthropy-backed gene therapy approach and IgAN data from Kidney Week, led by Otsuka's Voyxact, whose full two-year results showed it halting disease progression. The episode closed with ESMO 2026, including Moderna and Merck's data and Genmab's run of successes, which largely addresses its 2029/2030 royalty cliff. *This episode aired on October 30, 2026.
On this week's 200th episode, Daphne Zohar, Brad Loncar, Chris Garabedian, Sam Fazeli, Eric Schmidt, Josh Schimmer, Matt Gline, and special guest former Silence CEO Ali Mortazavi kicked off by reflecting on five years of Biotech Hangout, including the show's role as an “open door” resource for those across the industry. The co-hosts then discussed Moderna's stock dip after leaked ESMO 2026 data and how outsized market hopes for the cancer vaccine shaped the reaction. Matt expanded on his "woodchipper" analogy from his STAT Summit panel, while the group examined degrossing as a structural pressure on the sector. They also covered the Endpoints sentiment index turning positive for the first time since the pandemic. In deals, the group discussed Merck KGaA's $1.1 billion acquisition of Silence for its siRNA polycythemia vera candidate, with the company's former CEO, Ali Mortazavi, reflecting on its journey and the future of biotech structure in an AI world. The group also highlighted Lilly CEO Dave Ricks' growing X presence, signs of more big pharma deals ahead in a year tracking toward the second most active for M&A, and how options-driven trading around Abivax is distorting sentiment. The episode closed with reflections on the biggest surprises of the past five years and a look ahead to 2031. *This episode aired on October 23, 2026.
On this week’s episode, Graig Suvannavejh, Paul Matteis, Brian Skorney, Yaron Werber, and Jake Becraft opened with a look at the biotech market, with the XBI down roughly 700 basis points in two weeks but still up about 20% year to date. The IPO window remains open, though M&A has quieted. The co-hosts then discussed degrossing, overviewing a Goldman Sachs report that showed degrossing at the largest in over five years. The group also covered valuations, rate and midterm uncertainty, and M&A as a potential catalyst. In data news, the group discussed BMS’ admilparant in IPF, where only the low dose reached significance, and the read-through to Contineum. Next, they discussed Mirum’s Livmarli success in cholestatic pruritus, and celiac programs from Teva, argenx, and First Tracks, which all showed encouraging early data,ahead of November’s celiac meeting. The group also covered argenx’s Sjögren’s futility termination, Arrowhead’s first clinical data for a TfR-delivered tau siRNA, Alector’s brain shuttle update and $75 million raise, and Verastem’s KRAS G12D inhibitor data in pancreatic cancer. The episode closed with a preview of Moderna and Merck’s cancer vaccine data at ESMO 2026 and the open question of its placebo control. *This episode aired on October 16, 2026.
On this week's episode, Graig Suvannavejh, Sam Fazeli, Eric Schmidt, and Brian Skorney open with a look at the public markets, noting the XBI is up 27% year-to-date but down about 9% since its August high. The co-hosts then touched on Oura's pulled IPO, seeing little read-through for the broader biotech space. In deals, Sanofi and Regeneron extended their antibody collaboration for $1 billion upfront and up to $7 billion in milestones, while AstraZeneca and Daiichi Sankyo struck deals with Summit Therapeutics worth $2 billion in equity and pipeline access ahead of its high-stakes HARMONi-3 readout. Several additional licensing deals with Chinese biotechs were also announced. On approvals, the FDA cleared Mirum's FOP drug and AbbVie's novel D1/D5 Parkinson's therapy Juvmo (tavapadon). In data news, Dyne shared Phase 1/2 DM1 results, Kodiak's wet AMD combination hit its primary endpoint, Immix Biopharma reported positive interim AL amyloidosis data, and uniQure's Huntington's gene therapy data was also highlighted, prompting a broader group discussion on the challenges facing gene therapy. The episode closed with recaps of World Conference on Lung Cancer (WCLC) and European Association for the Study of Diabetes (EASD) touching on lung cancer bispecifics and strong new obesity data from Lilly. This episode aired on October 2, 2026.
On this week's episode, Sam Fazeli, Yaron Werber, Brian Skorney, and Matt Gline open with the IPO market, noting record average raise sizes even as XBI softens. The group turns to policy, unpacking newly FOIA-disclosed details of Pfizer's MFN agreement, including a revenue-share provision tied to price increases abroad. The co-hosts call the equalization concept constructive but warn cash-strapped European governments may ration access rather than pay more. They also discuss FDA commissioner nominee Heidi Overton's confirmation hearing, where innovation-forward opening remarks were read as a positive signal despite lingering questions about her MAHA alignment. In data news, Compass Therapeutics pushed ahead with bispecific tovecimig despite FDA’s request for an overall-survival trial, while Vertex's inaxaplin data broadened the case for efficacy beyond FSGS kidney patients. Amgen's dazodalibep for Sjögren's hit its primary endpoint in a Phase 3 trial, and Viking's VK2735 posted strong Phase 1 maintenance-dosing data in obesity. Celdex's barzolvolimab cleared both primary and secondary endpoints in urticaria, and Alkermes' ALKS 7290 succeeded in ADHD, adding to orexin-agonist momentum. The episode closed with Moderna's melanoma vaccine data tapped for ESMO's top plenary slot and Lexeo's $8.3 billion acquisition of Mantle Therapeutics. *This episode aired on September 25, 2026.
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
Listeners also like.

The Long Run with Luke Timmerman
In-depth conversations with biotech leaders navigating the challenges and opportunities of advancing science for human health.

The VPZD Show
Two physicians discuss healthcare, medicine, and policy from a contrarian, middle-ground perspective.

The Compound and Friends
Expert analysis and candid discussions on business and investing trends with a rotating panel of financial professionals.

After Hours
Three Harvard Business School professors discuss current events where business meets culture, offering insightful and unconventional takes.

TBPN
Daily tech talk show featuring interviews with prominent tech leaders and condensed highlights of key discussions.

Dope Labs
Two scientist best friends break down trending topics through a scientific lens, making complex concepts accessible and entertaining.

The a16z Show
Explores technology and cultural shifts shaping the future through conversations with industry leaders and innovators.

Bringing Chemistry to Life
Talks with leading chemists about their discoveries, careers, and the science shaping our world.

Biostatistics Podcast
A podcast exploring various topics in biostatistics.

The Genomics Lab
Olivia Grant

Curiosity Weekly
A science podcast breaking down recent discoveries in fields like neuroscience, climate tech, AI, and genetics with expert interviews.

Solutions with Henry Blodget
Henry Blodget interviews experts in business, tech, and politics about practical solutions for building a better future.
A weekly discussion of all things biotech – breaking news, data, deals, and FDA actions – with a community of biotech industry leaders and experts. Join the live streams hosted by @BiotechCH, @daphnezohar, @bradloncar and @biotech1 on Twitter Spaces every Friday at 12pm ET.
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from Biotech Hangout in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of Biotech Hangout as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more.
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
Biotech Hangout publishes weekly. Our AI generates a summary within hours of each new episode.
Biotech Hangout covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.